Artificial intelligence is rapidly transforming thoracic radiology across India and the globe. However, clinicians need to know if the scientific evidence supports using AI pulmonary nodule assessment in daily practice. Consequently, a recent systematic review evaluated 95 studies to map the clinical efficacy of these commercial tools.
Evolving Focus of AI Pulmonary Nodule Assessment
Historically, early research on thoracic AI focused strictly on basic technical performance. Specifically, between 2012 and 2017, over 83% of studies focused on technical efficacy and diagnostic accuracy. During this initial phase, developers primarily designed AI applications to perform simple nodule quantification. Conversely, only a minor fraction of studies addressed advanced clinical tasks like malignancy prediction.
Fortunately, the research landscape has shifted dramatically in recent years. Moreover, by 2024, over a third of studies investigated clinical outcomes like diagnostic thinking and therapeutic efficacy. Furthermore, studies on malignancy prediction increased to nearly 29%, while nodule characterization emerged as a key area of study. This evolution represents a major shift from technical validation to real-world clinical utility.
Critical Gaps and Funding Biases in Radiology AI
Despite these rapid technological advancements, critical gaps remain in the scientific literature. For instance, very few studies evaluate patient outcomes or long-term cost-effectiveness. Therefore, radiologists in India must interpret AI recommendations with a degree of healthy skepticism. Additionally, methodological quality remains a significant concern for early adopters.
Specifically, the review revealed that all 95 studies demonstrated a high risk of bias in at least one domain. Consequently, this widespread bias raises concerns about the reliability of commercial claims. Furthermore, nearly two-thirds of these studies involved vendor funding or co-authorship. As a result, healthcare institutions must demand independent, peer-reviewed validation before integrating these tools into their screening workflows.
Recommendations for Indian Radiologists
For Indian diagnostic centers facing massive patient volumes, AI software offers clear operational advantages. However, clinicians should not view these systems as completely autonomous decision-makers. Instead, radiologists must utilize AI strictly as a supportive second reader to avoid over-reliance.
Furthermore, hospital procurement committees must actively scrutinize the research behind commercial products. Specifically, they should prioritize tools validated by independent researchers rather than vendor-funded trials. Consequently, clinical teams can ensure they deploy safe, highly accurate technologies that truly improve patient outcomes.
Frequently Asked Questions
Q1: What is the primary limitation of current AI tools for pulmonary nodule assessment?
While technology has advanced rapidly, most published studies exhibit a high risk of bias. Furthermore, vendor-funded trials dominate the existing research, leaving limited evidence regarding actual patient outcomes or cost-effectiveness.
Q2: How has the focus of AI research in thoracic imaging changed over time?
Initially, early studies focused almost exclusively on basic technical performance and simple nodule quantification. However, by 2024, research increasingly shifted toward evaluating clinical efficacy, therapeutic impact, and malignancy risk prediction.
Q3: Should Indian diagnostic laboratories rely completely on AI for lung nodule detection?
Indeed, clinical guidelines suggest using AI strictly as a supportive second reader. Consequently, radiologists must always review AI findings to prevent errors stemming from vendor bias or software discordance.
References
- Paramasamy J et al. Scientific evidence of commercial artificial intelligence products for pulmonary nodule assessment on CT scans: a systematic review. Eur Radiol. 2026 Jul 15. doi: 10.1007/s00330-026-12745-8. PMID: 42448899.
- Liao X, Tian Y, Cheng Y, Sun X, Li Y, Zhao Z, et al. Evaluating the diagnostic performance of artificial intelligence-assisted decision-making software for pulmonary nodules in a resource-limited setting: Insights from a secondary hospital in China. J Clin Imaging Sci. 2026;16:6. doi: 10.25259/JCIS_212_2025.
- Antonissen N et al. Commercially available AI products for CT-based lung cancer screening: capabilities, clinical evidence, and alignment with international screening frameworks. European Congress of Radiology 2026.